{"id":588,"date":"2015-08-28T17:33:46","date_gmt":"2015-08-28T15:33:46","guid":{"rendered":"http:\/\/swedenbio.se\/?post_type=medlemmar&#038;p=588"},"modified":"2021-03-02T12:54:58","modified_gmt":"2021-03-02T11:54:58","slug":"hansa-medical-ab","status":"publish","type":"medlemmar","link":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/","title":{"rendered":"Hansa Biopharma"},"content":{"rendered":"<p>Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company&#8217;s lead candidate drug, <em class=\"wa-italic\">IdeS,<\/em> is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company&#8217;s lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.<\/p>\n","protected":false},"author":1,"featured_media":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"user_categories":[44,6],"class_list":["post-588","medlemmar","type-medlemmar","status-publish","hentry","user_categories-life-science-companies","user_categories-pharma"],"acf":[],"aioseo_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hansa Biopharma - SwedenBIO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansa Biopharma - SwedenBIO\" \/>\n<meta property=\"og:description\" content=\"Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company&#8217;s lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/\" \/>\n<meta property=\"og:site_name\" content=\"SwedenBIO\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-02T11:54:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/hansa-medical-ab\\\/\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/hansa-medical-ab\\\/\",\"name\":\"Hansa Biopharma - SwedenBIO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#website\"},\"datePublished\":\"2015-08-28T15:33:46+00:00\",\"dateModified\":\"2021-03-02T11:54:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/hansa-medical-ab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/hansa-medical-ab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/hansa-medical-ab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansa Biopharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\",\"name\":\"SwedenBIO\",\"description\":\"Branschorganisationen f\u00f6r svenska life science f\u00f6retag\",\"publisher\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#organization\",\"name\":\"SwedenBIO\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/swedenbio.se\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo.png\",\"width\":240,\"height\":59,\"caption\":\"SwedenBIO\"},\"image\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hansa Biopharma - SwedenBIO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/","og_locale":"en_US","og_type":"article","og_title":"Hansa Biopharma - SwedenBIO","og_description":"Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company&#8217;s lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.","og_url":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/","og_site_name":"SwedenBIO","article_modified_time":"2021-03-02T11:54:58+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/","url":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/","name":"Hansa Biopharma - SwedenBIO","isPartOf":{"@id":"https:\/\/swedenbio.se\/en\/#website"},"datePublished":"2015-08-28T15:33:46+00:00","dateModified":"2021-03-02T11:54:58+00:00","breadcrumb":{"@id":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/swedenbio.se\/en\/medlemmar\/hansa-medical-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/swedenbio.se\/en\/"},{"@type":"ListItem","position":2,"name":"Hansa Biopharma"}]},{"@type":"WebSite","@id":"https:\/\/swedenbio.se\/en\/#website","url":"https:\/\/swedenbio.se\/en\/","name":"SwedenBIO","description":"Branschorganisationen f\u00f6r svenska life science f\u00f6retag","publisher":{"@id":"https:\/\/swedenbio.se\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/swedenbio.se\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/swedenbio.se\/en\/#organization","name":"SwedenBIO","url":"https:\/\/swedenbio.se\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/swedenbio.se\/en\/#\/schema\/logo\/image\/","url":"https:\/\/swedenbio.se\/wp-content\/uploads\/2020\/09\/logo.png","contentUrl":"https:\/\/swedenbio.se\/wp-content\/uploads\/2020\/09\/logo.png","width":240,"height":59,"caption":"SwedenBIO"},"image":{"@id":"https:\/\/swedenbio.se\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar"}],"about":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/types\/medlemmar"}],"author":[{"embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/comments?post=588"}],"version-history":[{"count":3,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/588\/revisions"}],"predecessor-version":[{"id":23646,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/588\/revisions\/23646"}],"wp:attachment":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/media?parent=588"}],"wp:term":[{"taxonomy":"user_categories","embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/user_categories?post=588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}